Design and development of highly conserved, HLA-promiscuous T cell multiepitope vaccines against human visceral leishmaniasis

IntroductionNo vaccine is currently licensed against human visceral leishmaniasis (VL), a fatal CD4+ T cell immunosupressive disease against which chemotherapy is reduced to a few toxic drugs. The NH36 nucleoside hydrolase is a DNA metabolism vital enzyme present in all Leishmania species. A vaccine...

Full description

Saved in:

Bibliographic Details
Main Authors:	Aline Silva Barreto, Mariana Nobre Farias de Franca, Tatiana Leão dos Santos dos Reis, Joao Antonio Barbosa Martins Silva, Priscila Lima Dos Santos, Fabrícia Alvisi de Oliveira, Angela Maria da Silva, Lucas Sousa Magalhaes, Danielle Angst Secco, Maria Aiza Fontes Andrade, Luís Cristóvão Porto, Daniela Santoro Rosa, Rafael Ciro Marques Cavalcante, Cristiane Bani Corrêa, John Sidney, Alessandro Sette, Roque Pacheco de Almeida, Clarisa Beatriz Palatnik-de-Sousa
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-03-01
Series:	Frontiers in Immunology
Subjects:	multiepitope based vaccines leishmaniosis visceral leishmaniosis HLA class I and class II promiscuous epitopes Leishmania conserved antigens
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2025.1540537/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!

Design and development of highly conserved, HLA-promiscuous T cell multiepitope vaccines against human visceral leishmaniasis

Similar Items